Zacks Research Weighs in on Zimmer Biomet FY2024 Earnings

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Analysts at Zacks Research reduced their FY2024 EPS estimates for Zimmer Biomet in a research report issued to clients and investors on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $7.98 for the year, down from their prior forecast of $7.99. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q3 2025 earnings at $1.98 EPS, Q4 2025 earnings at $2.38 EPS, FY2025 earnings at $8.51 EPS, Q3 2026 earnings at $2.21 EPS and FY2026 earnings at $9.18 EPS.

Other equities research analysts have also recently issued research reports about the company. TD Cowen dropped their price objective on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a report on Friday, September 6th. JPMorgan Chase & Co. reduced their price objective on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a research report on Monday, September 16th. BTIG Research cut their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research note on Thursday, October 3rd. Raymond James cut their price objective on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Finally, Evercore ISI decreased their target price on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average price target of $123.22.

Zimmer Biomet Stock Up 1.7 %

Shares of NYSE ZBH opened at $110.22 on Friday. The firm’s fifty day moving average is $106.79 and its 200 day moving average is $109.69. Zimmer Biomet has a 52 week low of $101.47 and a 52 week high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The company has a market cap of $21.94 billion, a price-to-earnings ratio of 20.95, a PEG ratio of 1.99 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same period last year, the company earned $1.65 EPS. Zimmer Biomet’s revenue for the quarter was up 4.1% compared to the same quarter last year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were issued a $0.24 dividend. The ex-dividend date was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.87%. Zimmer Biomet’s payout ratio is currently 18.25%.

Hedge Funds Weigh In On Zimmer Biomet

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Seven Eight Capital LP purchased a new position in Zimmer Biomet in the 1st quarter worth about $296,000. Bessemer Group Inc. lifted its position in Zimmer Biomet by 13.0% during the first quarter. Bessemer Group Inc. now owns 4,220 shares of the medical equipment provider’s stock valued at $557,000 after purchasing an additional 487 shares during the period. Pitcairn Co. boosted its holdings in Zimmer Biomet by 17.2% in the first quarter. Pitcairn Co. now owns 2,657 shares of the medical equipment provider’s stock worth $351,000 after purchasing an additional 389 shares during the last quarter. Crewe Advisors LLC bought a new stake in Zimmer Biomet in the 1st quarter worth approximately $31,000. Finally, EP Wealth Advisors LLC purchased a new stake in Zimmer Biomet during the first quarter valued at $282,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.